Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Press Releases

Month Year

Month Year

Get News Alerts by Email

Mar 6, 2023

Cardiff Oncology Formally Introduces Scientific Advisory Board
Mar 2, 2023

Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Feb 27, 2023

Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
Feb 2, 2023

Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
- Photos 1
Jan 10, 2023

Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference
Nov 21, 2022

Cardiff Oncology to Present at Upcoming Investor Conferences
Nov 8, 2022

Cardiff Oncology to Present at the Jefferies London Healthcare Conference
Nov 3, 2022

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
Sep 12, 2022

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates
Sep 10, 2022

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022
Sep 8, 2022

Cardiff Oncology to Present at Upcoming Investor Conferences in September
Sep 6, 2022

Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022
Aug 29, 2022

Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022
Aug 4, 2022

Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates
Jul 5, 2022

Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022
May 17, 2022

Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
May 5, 2022

Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates
Apr 12, 2022

Cardiff Oncology Announces Departure of Chief Medical Officer
Apr 8, 2022

Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models
Apr 8, 2022

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting
Mar 22, 2022

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC
Mar 8, 2022

Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting
Mar 1, 2022

Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference
Feb 24, 2022

Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights

- Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer program continues to show an objective response rate and median progression-free survival that substantially exceed those seen in historical control trials
Jan 31, 2022

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Show per page